Enlivex Therapeutics stock gains on upcoming Q1 2026 earnings and steep year-to-date decline

Enlivex Therapeutics stock (ISIN IL0011283620) last closed on Nasdaq at USD 0.81 on September 18, 2026, after a gain of 10.92 percent versus the prior close at USD 0.73 based on data from MarketBeat for the latest completed trading day.

Stock under pressure despite recent rebound

According to MarketBeat on September 18, 2026, Enlivex Therapeutics stock traded in a one-year range between a 52-week low of USD 0.64 and a 52-week high of USD 27.15, highlighting how far the current price stands below last year’s peak level.

The same overview from MarketBeat states that Enlivex Therapeutics had a market capitalization of USD 14.11 million as of the latest data snapshot in mid September 2026, derived from the Nasdaq share price and the number of shares outstanding.

Year-to-date performance and valuation context

As reported by MarketBeat in its performance commentary updated in September 2026, Enlivex Therapeutics stock was trading at USD 10.5480 at the beginning of 2026 and has since decreased by 92.4 percent to around USD 0.81, underscoring the magnitude of the drawdown for shareholders over the year to date.

For investors, this steep decline combined with the current market capitalization in the tens-of-millions of USD range places Enlivex Therapeutics among the higher-risk, small-cap biotech names where individual clinical and regulatory milestones can have outsized impact on the share price trajectory.

Upcoming Q1 2026 earnings as near-term catalyst

According to the Q1 2026 earnings calendar entry for Enlivex Therapeutics on MarketBeat, the company is scheduled to announce its Q1 2026 earnings on September 25, 2026 before the market opens, providing the next formal update on its financial position and operating progress.

The same earnings page from MarketBeat lists a consensus earnings per share expectation of minus USD 0.31 for Q1 2026, indicating that analysts continue to anticipate losses as Enlivex Therapeutics invests in clinical development rather than generating commercial revenue at this stage.

Fundamental backdrop and guidance context

As a clinical-stage biotechnology company, Enlivex Therapeutics focuses on cell-based immunotherapies designed to restore immune-system balance, aiming to treat severe or dysregulated inflammation using its Allocetra platform, according to the company profile provided by MarketBeat in September 2026.

Because Enlivex Therapeutics remains in the clinical stage, recent earnings releases typically highlight operating expenses, cash runway and clinical trial timelines rather than traditional profitability metrics, and the upcoming Q1 2026 report on September 25, 2026 is expected to update investors on trial progression and funding capacity alongside the reported loss per share.

Analyst view and price target signal

The same stock overview on MarketBeat indicates that Enlivex Therapeutics currently holds a consensus rating of Moderate Buy and summarizes a consensus price target of USD 247.50 as of mid September 2026, far above the latest Nasdaq price near USD 0.81 and illustrating the large gap between valuation models and the market quotation.

For investors, this combination of a Moderate Buy consensus stance and a triple-digit USD price target on one side, versus a sub-USD share price and a year-to-date drop of over 90 percent on the other side, underlines that expectations are highly sensitive to clinical data outcomes and financing developments, making the Q1 2026 earnings report on September 25, 2026 a key checkpoint for reassessing risk and potential reward.

Enlivex Therapeutics stock price level

Based on MarketBeat data for the latest completed trading day, Enlivex Therapeutics stock closed on Nasdaq at USD 0.81 on September 18, 2026, with an intraday gain of 10.92 percent versus the prior closing price, and a market capitalization of approximately USD 14.11 million as of that date.

More news and analyses on Enlivex Therapeutics stock